Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
November 11, 2024 08:00 ET
|
Autonomix Medical, Inc.
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6...
Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction
October 31, 2024 08:00 ET
|
Autonomix Medical, Inc.
79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure Company reaches 60% enrollment with 15 patients1 successfully enrolled; No unexpected...
ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS
October 28, 2024 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that...
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Molecular Oncology Market Size is projected to Reach USD 7.4 billion, Garnering an 11.0% by 2034: Transparency Market Research Inc.
October 11, 2024 08:41 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The global molecular oncology market (분자종양학 시장) was projected to attain US$ 2.3 billion in...
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress
October 09, 2024 07:07 ET
|
Panavance Therapeutics Inc.
Misetionamide-gemcitabine combination demonstrates very good safety profile and potential therapeutic benefit in the challenging treatment of pancreatic adenocarcinoma Interim results show ~40% of...
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
Oncology Collaboration and Licensing Agreements Analysis Report 2024: SEC-Linked Oncology Contract Documents Reveal In-Depth Deal Structures and Payment Clauses
September 30, 2024 05:03 ET
|
Research and Markets
Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offeringThe report provides access to deal...
Urteste Expands Development of Innovative Diagnostic Projects
September 26, 2024 10:29 ET
|
Urteste S.A.
Urteste Expands Development of Innovative Diagnostic Projects Gdańsk, Poland – 26 SEPTEMBER 2024, 16:00 CET - Urteste S.A. (Warsaw Stock Exchange: URT), a biotechnology company...